Two Sigma Advisers’s Edwards Lifesciences EW Stock Holding History

Two Sigma Advisers’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-110,006	Closed	-$9.38M	–	719
2025 Q4	$9.38M	Buy	110,006 +22,600	+26%	+$1.85M	0.02%	564
2025 Q3	$6.8M	Buy	+87,406	New	+$6.83M	0.01%	633
2024 Q4	–	Sell	-33,003	Closed	-$2.18M	–	2388
2024 Q3	$2.18M	Buy	+33,003	New	+$2.4M	0.01%	1022
2024 Q2	–	Sell	-208,506	Closed	-$19.9M	–	2513
2024 Q1	$19.9M	Sell	208,506 -1,265,197	-86%	-$106M	0.05%	344
2023 Q4	$112M	Sell	1,473,703 -102,200	-6%	-$7.11M	0.26%	90
2023 Q3	$109M	Sell	1,575,903 -172,500	-10%	-$13.9M	0.28%	89
2023 Q2	$165M	Sell	1,748,403 -866,800	-33%	-$75.3M	0.42%	64
2023 Q1	$216M	Sell	2,615,203 -888,600	-25%	-$69.8M	0.56%	39
2022 Q4	$261M	Buy	3,503,803 +2,164,100	+162%	+$167M	0.73%	25
2022 Q3	$111M	Buy	1,339,703 +281,900	+27%	+$27.1M	0.32%	76
2022 Q2	$101M	Sell	1,057,803 -108,700	-9%	-$11.3M	0.29%	86
2022 Q1	$137M	Sell	1,166,503 -711,500	-38%	-$79.8M	0.37%	64
2021 Q4	$243M	Buy	1,878,003 +65,700	+4%	+$7.66M	0.61%	46
2021 Q3	$205M	Buy	1,812,303 +1,287,400	+245%	+$147M	0.53%	44
2021 Q2	$54.4M	Buy	524,903 +255,500	+95%	+$24.1M	0.14%	142
2021 Q1	$22.5M	Buy	+269,403	New	+$22.8M	0.06%	335
2020 Q4	–	Sell	-45,815	Closed	-$3.66M	–	2449
2020 Q3	$3.66M	Sell	45,815 -1,825,794	-98%	-$142M	0.01%	879
2020 Q2	$129M	Buy	1,871,609 +916,700	+96%	+$65.1M	0.38%	53
2020 Q1	$60M	Sell	954,909 -867,600	-48%	-$62.6M	0.23%	106
2019 Q4	$142M	Buy	1,822,509 +1,052,100	+137%	+$82.2M	0.33%	68
2019 Q3	$56.5M	Buy	770,409 +34,800	+5%	+$2.44M	0.14%	175
2019 Q2	$45.3M	Buy	+735,609	New	+$44.5M	0.11%	225
2018 Q4	–	Sell	-344,661	Closed	-$20M	–	2380
2018 Q3	$20M	Sell	344,661 -399,006	-54%	-$19.5M	0.05%	395
2018 Q2	$36.1M	Sell	743,667 -1,535,400	-67%	-$71.7M	0.1%	254
2018 Q1	$106M	Sell	2,279,067 -286,500	-11%	-$12.4M	0.29%	88
2017 Q4	$96.4M	Buy	2,565,567 +2,289,000	+828%	+$84M	0.26%	103
2017 Q3	$10.1M	Buy	276,567 +151,200	+121%	+$5.77M	0.03%	561
2017 Q2	$4.94M	Buy	125,367 +109,800	+705%	+$4.01M	0.02%	758
2017 Q1	$488K	Buy	+15,567	New	+$487K	﹤0.01%	1906
2016 Q4	–	Sell	-1,529,022	Closed	-$61.4M	–	2367
2016 Q3	$61.4M	Buy	1,529,022 +48,900	+3%	+$1.84M	0.26%	96
2016 Q2	$49.2M	Buy	1,480,122 +738,900	+100%	+$25.3M	0.25%	98
2016 Q1	$21.8M	Sell	741,222 -682,680	-48%	-$18.8M	0.12%	197
2015 Q4	$37.5M	Buy	1,423,902 +1,037,400	+268%	+$26.9M	0.22%	124
2015 Q3	$9.16M	Sell	386,502 -691,200	-64%	-$16.7M	0.06%	347
2015 Q2	$25.6M	Sell	1,077,702 -1,448,514	-57%	-$32.7M	0.19%	143
2015 Q1	$60M	Sell	2,526,216 -310,800	-11%	-$6.97M	0.44%	42
2014 Q4	$60.2M	Sell	2,837,016 -1,456,200	-34%	-$29.3M	0.47%	34
2014 Q3	$73.1M	Buy	4,293,216 +907,800	+27%	+$14.3M	0.55%	27
2014 Q2	$48.4M	Sell	3,385,416 -192,000	-5%	-$2.6M	0.38%	51
2014 Q1	$44.2M	Sell	3,577,416 -735,000	-17%	-$8.48M	0.4%	47
2013 Q4	$47.3M	Buy	4,312,416 +2,425,200	+129%	+$27.3M	0.46%	38
2013 Q3	$21.9M	Buy	+1,887,216	New	+$22.1M	0.26%	79

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Two Sigma Advisers's EW Position: Q1 2026 in Review

Two Sigma Advisers sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 110,006 shares — an estimated $9.38M sold.

Two Sigma Advisers first reported a position in EW in Q3 2013 and held it in 42 quarters. The position peaked at $261M in Q4 2022. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Two Sigma Advisers reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 110,006 Edwards Lifesciences shares in Q1 2026, an estimated $9.38M.
Two Sigma Advisers first reported a position in Edwards Lifesciences in Q3 2013 and held it in 42 quarters.
Two Sigma Advisers's Edwards Lifesciences position peaked at $261M in Q4 2022.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.